Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VBI Vaccines Inc VBIV

Healthcare Biotechnology
VBI Vaccines Inc. is a commercial stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology, The Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The Company is focused on targeting and overcoming infectious diseases, including hepatitis B (HBV), COVID-19, and coronaviruses, and cytomegalovirus (CMV), as well as cancers, including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for corona virus disease include VBI-2901, VBI-2905, VBI-2902, and other. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2501 is its Prophylactic Candidate for Zika virus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.


NDAQ:VBIV - Post by User

VBI Vaccines Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Post by Iownyoudailyon Sep 09, 2020 2:53pm
238 Views
Post# 31527745

TARGET SET to $9 USD BY RAYMOND JAMES $VBIV #STRONGBUY

TARGET SET to $9 USD BY RAYMOND JAMES $VBIV #STRONGBUY
 

Analyst Actions: Raymond James Upgrades VBI Vaccines to Strong Buy From Outperform, Lifts Price Target to $9 From $8

7:37AM ET on Thursday Aug 27, 2020 by MT Newswires
Companies Mentioned: VBIV
 

07:37 AM EDT, 08/27/2020 (MT Newswires) -- VBI Vaccines (VBIV) has an average buy rating among analysts, with an average price target of $6.

Analyst Actions: Raymond James Upgrades VBI Vaccines to Strong Buy From Outperform, Lifts Price Target to $9 From $8

7:37AM ET on Thursday Aug 27, 2020 by MT Newswires
Companies Mentioned: VBIV
 

07:37 AM EDT, 08/27/2020 (MT Newswires) -- VBI Vaccines (VBIV) has an average buy rating among analysts, with an average price target of $6.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities